Nexavar First FDA-Approved Drug Therapy for Li...(nual and interim reports filed with the ...),Health

This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the timing, progress and results of the clinical development, regulatory processes, and commercialization efforts of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals Inc.

References

(1) World Health Organization. Hepatitis B. Available at:

http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/.

Accessed April 10, 2007

(2) Penn State Milton S. Hershey Medical Center College of Medicine.

Malignant Hepatoma. Available at:

http://www.hmc.psu.edu/healthinfo/m/malignanthepatoma.htm. Accessed

April 10, 2007.

(3) International
'/>"/>